Article

Functional differences between D(1) and D(5) revealed by high resolution imaging on live neurons.

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Neuroscience (Impact Factor: 3.33). 09/2009; 164(2):463-9. DOI: 10.1016/j.neuroscience.2009.08.052
Source: PubMed

ABSTRACT The interaction between the dopaminergic and glutamatergic systems governs normal behavior and is perturbed in many psychiatric disorders including schizophrenia. Hypofunction of the D1 family of receptors, to which the D(1) and D(5) subtypes belong, is a typical feature of schizophrenia. Here we have used confocal live cell imaging of neurons to examine the distinct roles of the D(1) and D(5) receptors in the intra-neuronal interaction with the glutamatergic system. Using fluorescently tagged D(1) or D(5) expressed in cultured striatal neurons, we show that both receptor subtypes are primarily transported via lateral diffusion in the dendritic tree. D(1) is to a much larger extent than D(5) expressed in spines. D(1) is primarily expressed in the head whereas D(5) is largely localized to the neck of the spine. Activation of N-methyl-D-aspartic acid (NMDA) receptors slowed the diffusion rate and increased the number of D(1) positive spines, while no effect on D(5) diffusion or spine localization could be observed. The observed differences between D(1) and D(5) can be attributed to structural differences in the C-terminus and its capacity to interact with NMDA receptors and PSD-95. Identification of a unique role of D(1) for the intra-neuronal interaction between the dopaminergic and glutamatergic systems will have implications for the development of more specific treatments in many neuropsychiatric disorders.

0 Bookmarks
 · 
135 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Excessive activation of the N-Methyl-D-Aspartate (NMDA) receptor and the neurotransmitter dopamine (DA) mediate neurotoxicity and neurodegeneration under many neurological conditions, including Huntington's disease (HD), an autosomal dominant neurodegenerative disease characterized by the preferential loss of medium spiny projection neurons (MSNs) in the striatum. PSD-95 is a major scaffolding protein in the postsynaptic density (PSD) of dendritic spines, where a classical role for PSD-95 is to stabilize glutamate receptors at sites of synaptic transmission. Our recent studies indicate that PSD-95 also interacts with the D1 DA receptor localized in spines and negatively regulates spine D1 signaling. Moreover, PSD-95 forms ternary protein complexes with D1 and NMDA receptors, and plays a role in limiting the reciprocal potentiation between both receptors from being escalated. These studies suggest a neuroprotective role for PSD-95. Here we show that mice lacking PSD-95, resulting from genetic deletion of the GK domain of PSD-95 (PSD-95-ΔGK mice), sporadically develop progressive neurological impairments characterized by hypolocomotion, limb clasping, and loss of DARPP-32-positive MSNs. Electrophysiological experiments indicated that NMDA receptors in mutant MSNs were overactive, suggested by larger, NMDA receptor-mediated miniature excitatory postsynaptic currents (EPSCs) and higher ratios of NMDA- to AMPA-mediated corticostriatal synaptic transmission. In addition, NMDA receptor currents in mutant cortical neurons were more sensitive to potentiation by the D1 receptor agonist SKF81297. Finally, repeated administration of the psychostimulant cocaine at a dose regimen not producing overt toxicity-related phenotypes in normal mice reliably converted asymptomatic mutant mice to clasping symptomatic mice. These results support the hypothesis that deletion of PSD-95 in mutant mice produces concomitant overactivation of both D1 and NMDA receptors that makes neurons more susceptible to NMDA excitotoxicity, causing neuronal damage and neurological impairments. Understanding PSD-95-dependent neuroprotective mechanisms may help elucidate processes underlying neurodegeneration in HD and other neurological disorders.
    Journal of neurogenetics 04/2014; · 0.73 Impact Factor
  • European Neuropsychopharmacology 08/2010; 20. · 5.40 Impact Factor
  • European Neuropsychopharmacology 08/2010; 20. · 5.40 Impact Factor

Full-text

Download
22 Downloads
Available from
Jul 7, 2014